Home › NDC Lookup › Ingredients › Bisoprolol Fumarate And Hydrochlorothiaz... › 00093-3243-56
⚪image loading
(from DailyMed)

bisoprolol fumarate and hydrochlorothiazide 10 mg; 6.25 mg Tablet, Film Coated, 30-count — NDC 0093-3243-56 (Billing 00093-3243-56)

by Teva Pharmaceuticals USA, Inc. · 30 TABLET, FILM COATED in 1 BOTTLE

This is a package of 30 tablets of bisoprolol fumarate and hydrochlorothiazide 10 mg; 6.25 mg Tablet, Film Coated from Teva Pharmaceuticals USA, Inc., marketed since Nov 2020 and currently FDA-listed; retail pharmacies pay about $0.2094 per tablet (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 00093-3243-56
🏷️ FDA NDC (as labeled) 0093-3243-56 billing pads the labeler segment with a zero
This package
Contains30-count Cost per ea$0.2094 NADAC Per package$6.28 / 30 tablets Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.3638/unit · Part D plans $0.4132/unit — full pricing hub ↓
Main listing for product 0093-3243 · Also comes in: 45845 tablets 0093-3243-99
On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0093-3243-56 alone.

Record
FDA NDC Directory package listing · Drug for further processing
Code segments
0093 labeler · 3243 product · 56 package
Package marketed since
Aug 7, 2019
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
30 EA per package
Barcode (UPC-A, from the NDC)
3 0093324356 8
Medicaid fills, this package
116 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026
⚠️
Other active recalls for Bisoprolol Fumarate And Hydrochlorothiazide (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Jan 21, 2026 — cGMP Deviations: recall due to not meeting the N-Nitroso Bisoprolol impurity specification limits. (Unichem Pharmaceuticals USA Inc.) · FDA recall D-0301-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0093-3243-56
Product NDC 0093-3243
11-digit billing NDC 00093324356
NCPDP billing unit EA — each (per item)
SPL Set ID 18cb0fc5-6e42-4c23-9114-dc4630ae2b18
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2020-11-23
Dosage form TABLET, FILM COATED
Substance BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 021141
GCN 45063
HICL code 008715
Ingredient (HICL) Bisoprolol/Hydrochlorothiazide
HIC1 code J
Therapeutic class — broad (HIC1) Autonomic Nervous System
HIC2 code J7
Therapeutic class — intermediate (HIC2) Antiadrenergics
HIC3 code J7H
Therapeutic class — specific (HIC3) Beta-Blockers And Thiazide,Thiazide-Like Diuretics
AHFS code 12:16.08.08
AHFS class Selective Beta-Adrenergic Blocking Agent
FDB label name BISOPROLOL-HCTZ 10-6.25 MG TAB
FDB brand name Bisoprolol-Hydrochlorothiazide
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 021141
  • GCN: 45063
  • HICL (First Databank): 008715
  • AHFS class code: 12:16.08.08
Why two NDCs? The FDA registers this code as 0093-3243-56 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00093-3243-56. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name BISOPROLOL-HCTZ 10-6.25 MG TAB Ingredient Bisoprolol/Hydrochlorothiazide
📖 About the active ingredient: Bisoprolol Fumarate; Hydrochlorothiazide MedlinePlus · NLM
General information about the ingredient itself — the description of this specific product follows below.

Bisoprolol is used to treat high blood pressure. Bisoprolol is in a class of medications called beta blockers. It works by relaxing blood vessels and slowing heart rate to improve and decrease blood pressure.

Read the full MedlinePlus article ↗
🧪 What is this product?

This listing is a prescription film-coated oral tablet containing two active ingredients: bisoprolol fumarate and hydrochlorothiazide. It is marketed as an NDA authorized generic, meaning it is a copy of a brand-name drug approved by the FDA. Bisoprolol is a beta-blocker, and hydrochlorothiazide is a thiazide diuretic, a class of "water pill." Together, this combination is typically used to treat high blood pressure (hypertension).

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.209 $6.28 / 30 tablets
Medicaid paysCMS SDUD · 12 mo $0.3638 $10.91 / 30 tablets
Medicare drug plans payPart D · Q2 2026 $0.4132 $12.40 / 30 tablets
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.368 $0.201
▼ Down 43% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00093-3243-56 You're viewing this Main listing 30 TABLET, FILM COATED in 1 BOTTLE $0.2094 / ea $6.28 2019-08-07 — Active
00093-3243-99 0093-3243-99 45845 TABLET, FILM COATED in 1 DRUM — — — — Active

You're viewing the smallest of 2 pack sizes for this product.

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 30-count package — 30 tablet, film coated in 1 bottle.
How does this package differ from NDC 00093-3243-99?
Both are bisoprolol fumarate and hydrochlorothiazide 10 mg; 6.25 mg Tablet, Film Coated — the drug itself is identical. This page's package is the 30-count one, while NDC 00093-3243-99 is the 45845 tablets package.
What NDC number is used to bill for this package of bisoprolol fumarate and hydrochlorothiazide 10 mg; 6.25 mg Tablet, Film Coated?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
bisoprolol fumarate and hydrochlorothiazide 10 mg/1; 6.25 mgthis 00093-3243-56 Teva 30 tablets $0.209 — Availability likely —
Bisoprolol Fumarate and Hydrochlorothiazide 10 mg/1; 6.25 mg 00378-0505-01 Mylan 100 tablets $0.209 AB Availability likely —
bisoprolol fumarate and hydrochlorothiazide 6.25 mg/1; 10 mg 29300-0189-01 Unichem 100 tablets $0.209 AB Availability likely —
Bisoprolol Fumarate and Hydrochlorothiazide 10 mg/1; 6.25 mg 42799-0922-01 Edenbridge 100 tablets $0.209 AB Availability likely —
Bisoprolol Fumarate and Hydrochlorothiazide 10 mg/1; 6.25 mg 68462-0880-01 GLENMARK 100 tablets $0.209 AB Availability likely —
Bisoprolol Fumarate and Hydrochlorothiazide 10 mg/1; 6.25 mg 70954-0414-10 ANI 30 tablets $0.209 AB Availability likely —
Bisoprolol Fumarate and Hydrochlorothiazide 10 mg/1; 6.25 mg 72578-0115-01 Viona 100 tablets $0.209 AB Availability likely —
Bisoprolol Fumarate and Hydrochlorothiazide 10 mg/1; 6.25 mg 10135-0742-05 Marlex 500 tablets — AB FDA listed —
Bisoprolol Fumarate and Hydrochlorothiazide 10 mg/1; 6.25 mg 50090-5905-00 A-S 30 tablets — AB FDA listed —
Bisoprolol Fumarate and Hydrochlorothiazide 10 mg/1; 6.25 mg 50090-6030-00 A-S 30 tablets — AB FDA listed —
Bisoprolol Fumarate and Hydrochlorothiazide 10 mg/1; 6.25 mg 59651-0680-01 Aurobindo 100 tablets — AB FDA listed —
Bisoprolol Fumarate and Hydrochlorothiazide 10 mg/1; 6.25 mg 70771-1762-01 Zydus 100 tablets — AB FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2020
On the market since
Nov 2020
📍
2026
Currently FDA-listed
6 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerTeva Pharmaceuticals USA, Inc.
Labeler code00093
First marketedNov 2020
Product typeDrug For Further Processing
Portfolio504 products on file

More NDCs from Teva Pharmaceuticals USA, Inc. labeler code 00093

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
116
Units reimbursed last 4 qtrs
5.1K
Gross reimbursed last 4 qtrs
$1.8K
Avg / prescription
$15.90
Avg / unit
$0.3638
Latest quarter Q1 2026
21Rx
Medicaid pays / ea
$0.3638
gross reimbursed
vs
NADAC / ea
$0.2094
acquisition cost
=
Spread
+$0.1544
+74% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
84% FFS 16% MCO
Fee-for-service · 98 Rx Managed care · 18 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 4,530 units · 23.1 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: 540 units · 5.8 per 100k residents NJ Massachusetts: no data reported MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
5.823.1
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 23.1 /100k
2 New Jersey 5.8 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
30 tablets this page00093-3243-56 116 Rx · $1,844
45845 tablets00093-3243-99 No Medicaid data
Drug total (last 4 qtrs): 116 Rx · 5,070 units · $1,844 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Bisoprolol fumarate and hydrochlorothiazide — the ingredient across all brands.

Top reported reactions

Headache50
Fatigue44
Nausea41
Pruritus39
Pain38
Hypertension37
Vomiting36

Age at onset

Child1
Adult16
Elderly10

Reporter sex

615 reports
Male · 34%
Female · 66%

Serious outcomes

Hospitalization263
Death53
Life-threatening38
Disabling32
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 15 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Teva Pharmaceuticals USA, Inc. supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Teva Pharmaceuticals USA, Inc.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 45845 tablets (00093-3243-99). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Teva Pharmaceuticals USA, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 00093-3242-01 · Teva 00093-3301-01 · Teva →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.